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Background: Group B streptococcus is the leading cause of infection in infants. Currently, intrapartum
antibiotic prophylaxis is the major strategy to prevent invasive group B streptococcus disease. However,
intrapartum antibiotic prophylaxis does not prevent maternal sepsis, premature births, stillbirths or
late-onset disease. Maternal vaccination may offer an alternative strategy. Multivalent polysaccharide
protein conjugate vaccine development is under way and a serocorrelate of protection is needed to
expedite vaccine licensure.
Objectives: The ultimate aim of this work is to determine the correlate of protection against the major
group B streptococcus disease-causing serotypes in infants in the UK. The aim of this feasibility study is to
test key operational aspects of the study design.
Design: Prospective cohort study of pregnant women and their infants in a 6-month period (1 July to
31 December 2018).
Setting: Five secondary and tertiary hospitals from London and South England. National iGBS disease
surveillance was conducted in all trusts in England and Wales.
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Participants: Pregnant women aged ≥ 18 years who were delivering at one of the selected hospitals and
who provided consent during the study period. There were no exclusion criteria.
Interventions: No interventions were performed.
Main outcome measures: (1) To test the feasibility of collecting serum at delivery from a large cohort
of pregnant women. (2) To test the key operational aspects for a proposed large serocorrelates study.
(3) To test the feasibility of collecting samples from those with invasive group B streptococcus.
Results: A total of 1823 women were recruited during the study period. Overall, 85% of serum samples
were collected at three sites collecting only cord blood. At the two sites collecting maternal, cord and
infant blood samples, the collection rate was 60%. A total of 614 women were screened for group B
streptococcus with a colonisation rate of 22% (serotype distribution: 30% III, 25% Ia, 16% II, 14% Ib,
14% V and 1% IV). A blood sample was collected from 34 infants who were born to colonised women.
Maternal and infant blood and the bacterial isolates for 15 newborns who developed invasive group B
streptococcal disease during the study period were collected (serotype distribution: 29% III, 29% II, 21% Ia,
7% Ib, 7% IV and 7% V).
Limitations: Recruitment and sample collection were dependent on the presence of research midwives
rather than the whole clinical team. In addition, individualised consent limited the number of women who
could be approached each day, and site set-up for the national surveillance study and the limited time
period of this feasibility study limited recruitment of all eligible participants.
Conclusions: We have verified the feasibility of collecting and processing rectovaginal swabs and blood
samples in pregnant women, as well as samples from those with invasive group B streptococcal disease.
We have made recommendations for the recruitment of cases within the proposed GBS3 study and for
controls both within GBS3 and as an extension of this feasibility study.
Future work: A large case–control study comparing specific immunoglobulin G levels in mothers whose
infants develop invasive group B streptococcal disease with those in colonised mothers whose infants do
not develop invasive group B streptococcal disease is recommended.
Trial registration: Current Controlled Trials ISRCTN49326091; IRAS project identification number 246149/REC
reference number 18/WM/0147.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 23, No. 67.
See the NIHR Journals Library website for further project information.
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GBS3 A multicentre prospective two-arm, parallel, cluster randomised controlled trial to test women for
group B streptococcus colonisation in late pregnancy or labour compared with the current risk based
strategy, with internal pilot and feasibility evaluation and parallel economic modelling for testing women.
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BPAIIG British Paediatric Allergy, Immunity
and Infection Group
CI confidence interval
CoP correlate of protection
CPS capsular polysaccharide
ECM enriched culture medium
EOD early-onset disease
GBS group B streptococcus
HRA Health Research Authority
IAP intrapartum antibiotic prophylaxis
iGBS invasive group B streptococcal
disease
IgG immunoglobulin G
LAT latex agglutination test
LOD late-onset disease
neonIN Neonatal Infection Network
NIHR National Institute for Health
Research
PCR polymerase chain reaction
RCOG Royal College of Obstetrics and
Gynaecology
REC Research Ethics Committee
REDCap Research Electronic Data Capture
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G roup B streptococcus is often carried by healthy women and usually causes no problems. Group Bstreptococcus may be passed from mother to child, primarily through the birth canal, and, in rare
cases, can cause serious disease (i.e. pneumonia, sepsis or meningitis) and even death in babies. It may
be possible to prevent group B streptococcus disease in babies by giving a vaccine to pregnant women.
The reason for vaccinating the mother is so that she can pass on protection (antibodies) during the
pregnancy to her baby. A vaccine is currently being developed against group B streptococcus that aims
to boost this protection. To help vaccine development progress faster, we need to find out how much
antibody is actually needed to protect babies from group B streptococcus disease. A large study is needed
to address this question; therefore, we have performed a feasibility study to assess the practicalities of
performing this large study. Specifically, we will assess (1) women’s willingness to participate in a swabbing
and cord blood study, (2) the ability to collect swabs and cord blood once recruited, (3) the ability to
identify group B streptococcus disease in this population and (4) the laboratory processing of samples.
We recruited 1823 pregnant women from five maternity units in England in a 6-month period: 22% of
all women delivering at all sites and 74% of those women who were approached. In three hospitals,
cord blood samples from 85% of 1201 women were collected. In two hospitals, we collected 60% of
maternal blood samples, 53% of cord blood samples and 99% of swabs from the vagina and rectum
from 622 women. A total of 22% of these women carried group B streptococcus in their vagina or gut
and we collected blood samples from 34 healthy babies born to these women. During the study, we
collected samples from 15 babies who had developed severe group B streptococcus disease; four babies
were born to women participating in the study and the rest were identified through national surveillance.
In conclusion, we have verified the feasibility of collecting and processing swabs from the vagina and
rectum and blood samples in pregnant women, as well as samples from babies who developed group B
streptococcus disease. In addition, we have identified a number of strategies that could be adopted in a
future study in order to increase recruitment and sample collection.
DOI: 10.3310/hta23670 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 67
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Carreras-Abad et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of





Group B streptococcus is the leading cause of sepsis and meningitis in newborns and young infants
worldwide. The most common clinical presentation is early-onset disease (i.e. occurring in newborns aged
< 7 days). Most cases can be prevented with antibiotics given in labour (intrapartum antibiotic prophylaxis).
However, intrapartum antibiotic prophylaxis does not prevent late-onset disease, stillbirths, preterm births
or maternal sepsis. Furthermore, the UK has experienced an increase in group B streptococcus in infants in
recent years (from 0.72 to 0.95 per 1000 live births between 2000 and 2014), despite a national prevention
strategy that was introduced in 2003. Therefore, alternative strategies, such as maternal vaccination, are
being explored to provide greater protection against all clinical presentations, as well as to reduce the use
of antibiotics and their potential negative consequences on infant immune development and antimicrobial
resistance.
There is evidence that maternally derived serotype-specific antibodies against group B streptococcus can
protect newborns and young infants against disease. To facilitate group B streptococcus vaccine licensure,
a serocorrelate of protection against the major group B streptococcus serotypes causing disease is needed.
Objectives
The overall aim of this study is to facilitate a national serocorrelate of protection against group B
streptococcus disease study in 2020 embedded within the National Institute for Health Research GBS3 trial.
The objective of this feasibility study was to test the key operational aspects of such a study.
The primary objective was to test the feasibility of collecting serum at delivery (maternal, cord or both)
from a large cohort of pregnant women.
First, we tested the following key operational aspects: enrolment rate of eligible women who were willing
to participate in the delivery blood collection study, maternal and/or cord blood collection rate, key clinical
data collection rate, and infant invasive group B streptococcal disease surveillance consent rate. Several
substudies were embedded, including rectovaginal swab consent and collection rates, rectovaginal group B
streptococcus colonisation rate and rectovaginal group B streptococcus serotype-specific colonisation rate,
infant blood sample consent rate, infant Guthrie card consent rate, and infant Guthrie card collection rate.
Second, we tested the feasibility of collecting samples (maternal and infant blood samples and the
bacterial isolate) from invasive group B streptococcal disease cases from the study cohort and from
national surveillance.
Finally, we assessed laboratory parameters important for the main study: the impact of timing of processing
and blood sample storage conditions on total immunoglobulin G concentrations; the serotype-specific
group B streptococcus anticapsular polysaccharide immunoglobulin G concentrations in maternal serum
and cord blood in subjects colonised with group B streptococcus at delivery; and the correlation between
two different culture techniques for detection of group B streptococcus in rectovaginal swabs: enrichment
culture medium and direct plating using selective agar.
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Methods
We carried out a prospective cohort study of pregnant women and their infants over a 6-month period
between 1 July and 31 December 2018. Participants were recruited from five maternity units in London
and South England (i.e. Croydon, East Surrey, Kingston, Poole and St George’s hospitals). The inclusion
criteria were all pregnant women aged ≥ 18 years delivering at one of the five selected hospitals during the
study period. As this was a feasibility study, there were no exclusion criteria. At Kingston and St George’s
hospitals, women consented to provide maternal and cord blood samples as well as a rectovaginal swab.
In addition, they were invited to participate in the infant blood sample collection substudy in which infants
from colonised mothers were randomised at 1, 2 or 3 months. Furthermore, we asked for consent to track
their Guthrie cards if they had group B streptococcus-positive swabs and/or group B streptococcus disease.
At Croydon, East Surrey and Poole hospitals, women were asked to participate in the cord blood collection
study only. Maternal blood samples were collected only if cord blood was not obtained.
A telephone call follow-up was made at 90 days after birth to assess whether or not infants had developed
invasive group B streptococcal disease. In addition, national surveillance was set up after the study started
to increase the number of cases detected and to test the feasibility of using national surveillance data to
identify cases.
All data were collected on Research Electronic Data Capture (REDCap; 8.1.8, Vanderbilt University,
Nashville, TN, USA) and we undertook a descriptive analysis using Stata® version 15 (StataCorp LP, College
Station, TX, USA). McNemar’s test was used to assess the exploratory objective comparing the two group B
streptococcus culture methods.
Results
During the study period, 1823 women were recruited, which was 22% (95% confidence interval 21% to
23%) of all women delivering at the five selected hospitals. A total of 1201 were recruited at the three sites
collecting cord blood only, where the serum sample collection rate was 85%. At two sites collecting maternal,
cord and rectovaginal swabs, 622 women were recruited and the serum sample collection rate was 60%.
The rectovaginal sample collection rate was 99% (614/622). We found a colonisation rate of 22% with the
following serotype distribution: 30% III, 25% Ia, 16% II, 14% Ib, 14% V and 1% IV. Furthermore, 34 infants
born to colonised mothers were randomised at 1, 2 or 3 months for blood sample collection.
Key clinical data were collected and recorded on REDCap in 90–100% of cases, except for two items that
were related to antibiotic prescription, at 65% and 54%, respectively. Owing to the short period of the
study, we made 16% of the 90-day follow-up telephone calls. However, the consent rate for making
calls was 100%. We collected maternal and infant blood and the bacterial isolate from all 15 infants who
developed invasive group B streptococcal disease. The serotype distribution in cases was 29% III, 29% II,
21% Ia, 7% Ib, 7% IV and 7% V.
There was no impact of time of spinning on total immunoglobulin G concentrations for periods of
time from 6 hours to 1 week. The serotype-specific group B streptococcus anticapsular polysaccharide
immunoglobulin G concentrations in maternal serum and cord blood in subjects colonised with group B
streptococcus at delivery demonstrated that we were able to identify antibodies in these women and that
antibodies generally declined between delivery and 3 months of life.
We found a significant difference (p < 0.001) between direct plating and enriched culture medium culture
methods for detection of group B streptococcus. Using an enriched culture medium before plating onto
selective agar identified 97% (116/120) of the total positive rectovaginal swabs, whereas direct plating
onto selective agar identified 75% (90/120).
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Conclusions
The feasibility study has been able to assess key operational aspects that are needed to define the correlates
of protection against invasive group B streptococcal disease in a future study. We identified a number of
factors that may account for the variability in recruitment and sample collection rates between sites. The need
for consenting on labour wards and the engagement of all clinical staff were identified as two key factors.
Future work
To define the serocorrelates of protection against the major disease-causing group B streptococcus
serotypes will require a case–control study of adequate size. We have previously estimated that this could
be achieved with around 150 cases of invasive group B streptococcal disease and 450 matched controls.
Cases
A sample size of 150 cases will require a cohort of > 180,000 women (based on the known national
incidence) and this is well within the sample size predicted for the GBS3 trial. We therefore propose that
cord samples are obtained from this number of women. We will discuss further with the GBS3 team
whether this would apply to all women in the trial or only those in particular groups (e.g. standard of
care group). The latter would be preferred as this group may well have a higher rate of invasive group B
streptococcal disease. Within the feasibility study we have been able to define the practical issues around
collecting, spinning, storing and transferring these samples. We have also identified the issues around
consenting women for this, and have identified retrospective consent as an acceptable and effective
method. We would also like to propose consideration of an opt-out approach, whereby pregnant women
receive information about cord blood collection, which is then undertaken unless the woman elects not to
participate. We will explore this approach further through parent groups, health-care worker discussions
and ethics committee advice.
Controls
As previously demonstrated, we require a control group of around 450 colonised women (3 : 1 matched to
cases). To obtain 450 controls requires swabs from 5000 women. Importantly, such women must not have
received intrapartum antibiotics. Again, within the feasibility study we have been able to define, in detail,
the practical issues around collecting these samples as well as the issues around consenting women.
We now have a network of hospitals that are able to undertake a study to collect samples from controls.
We believe that completing the recruitment of the control group within the GBS3 trial will be difficult.
One of the major reasons for this is that the majority of women in GBS3 who are identified as group B
streptococcus-colonised will go on to receive intrapartum antibiotic prophylaxis. They will not therefore be
suitable as controls. It is also clear from the GBS3 team that actually identifying women who have received
intrapartum antibiotic prophylaxis (on an individual level) will be problematic, as their current strategy is to
define antibiotic exposure on a unit level and they do not currently envisage capturing individual-level data.
We therefore wish to propose completing recruitment to the control group through the network of units
that we have established during the feasibility study. This will ensure that we have a complete and
well-defined control group in preparation for case collection during the GBS3 trial. The extension will also
allow completion of the kinetics substudy and will ensure that the methods for collecting cases are finalised.
Trial registration
This trial is registered as ISRCTN49326091 and as IRAS project identification number 246149/REC
reference number 18/WM/0147.
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Chapter 1 Background
G roup B streptococcus (GBS) is the leading cause of neonatal sepsis and meningitis in most countries.GBS is also an important cause of disease in pregnant women, immunocompromised adults and elderly
people.1 The highest incidence of invasive group B streptococcal disease (iGBS) is in the first 3 months of
life and the condition is traditionally divided into early-onset disease (EOD) (i.e. occurring in infants aged
< 7 days) or late-onset disease (LOD) (i.e. occurring in infants aged 7–89 days). GBS is an encapsulated
bacterium and 10 serotypes are described; five serotypes (i.e. Ia, Ib, II, III, V) account for 97% of iGBS.2
Overall, EOD accounts for 60–80% of iGBS in the first 3 months of life. Maternal colonisation with GBS in
the gastrointestinal or genital tract is a prerequisite for EOD, with vertical transmission occurring during or
just before birth. Around 20% of pregnant women are colonised with GBS3 and 1–2% of neonates who
are born to colonised women develop invasive disease in the absence of intrapartum antibiotic prophylaxis
(IAP).4 EOD can occur rapidly, with signs evident at birth or within 12 hours in most cases, typically
presenting with sepsis, pneumonia and/or meningitis.5
Group B streptococcus is present in all regions of the world and an estimated 21.7 million pregnant
women are colonised at any one time.3 In 2015, it was estimated that annually worldwide there were at
least 319,000 infants aged < 3 months with iGBS, resulting in 90,000 infant deaths and at least 10,000
children with disability related to GBS meningitis. Additionally, 33,000 maternal cases and 57,000 stillbirths
are attributed to GBS disease each year.6
The global burden of group B streptococcus is therefore high and
represents an unmet public health need
Intrapartum antibiotic prophylaxis can reduce the incidence of EOD, and many high-income countries have
established IAP policies. The incidence of EOD in the USA has declined significantly in the era of IAP and
the incidence is also generally declining in other countries adopting a swab-based screening policy.7,8
However, in some countries, particularly those adopting a risk-based IAP strategy, such as the Netherlands9
and the UK,10 recent increases in disease burden have been reported.
It is clear that even strict and universal implementation of IAP guidelines does not eliminate EOD,11,12 as
disease can occur because of limitations to IAP administration (e.g. in precipitate labour), in infants of
mothers who were negative on screening and where no risk factors are evident in labour.13 Most significantly,
IAP has no impact on GBS-related prematurity or stillbirths or LOD, where the burden of disease is substantial.
The majority of GBS meningitis occurs after the first week of life, so this particular burden remains. In the
USA and the UK, GBS is now the most common cause of bacterial meningitis in children aged < 5 years.14,15
Given the very early onset of neonatal GBS disease, the shortcomings of IAP-based prevention strategies
and the evidence that suggests that maternal antibodies acquired after natural exposure (when transmitted
transplacentally to the fetus) may protect the young infant from invasive infection,16 the prospect of
protecting mothers and their infants through vaccination in pregnancy is an attractive one. Possible
candidates for an effective vaccine include one or more of the conserved surface proteins or the capsular
polysaccharide (CPS).17
Multiple studies of CPS–protein conjugate vaccines in non-pregnant and, more recently, in pregnant
women have established the immunogenicity and safety of these candidates.17 Recent estimates suggest
that an effective GBS maternal vaccine (> 80% efficacy), with high (90%) global coverage, could prevent
231,000 infant and maternal GBS cases, 41,000 stillbirths and 66,000 infant deaths annually.6
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Several obstacles exist in moving the most advanced vaccines into Phase III clinical trials. The first is that,
given the relative rarity of GBS disease in Europe and the USA, large numbers of infants would need to be
recruited to determine vaccine efficacy.18 Second, obstacles exist in determining what concentration of
antibody is required to protect the infant for the duration of the at-risk period (i.e. the first 3 months of
life), as there are currently no internationally recognised standards with which to interpret individual study
results.1 Licensure and policy decisions would be significantly accelerated if an immune marker, measured
in an analytically and clinically validated assay, was established as a correlate of protection (CoP). Licensure
in such a scenario would come with a commitment to establish effectiveness post licensure in a Phase IV
study. This was the approach used for licensure of meningococcal C and meningococcal B vaccines.19
Correlates of protection against invasive disease
The association between serotype-specific capsular antibody levels and iGBS in newborns was initially
characterised in 1976 by Baker and Kasper.16 In the majority of subsequent studies, levels of CPS
serotype-specific antibodies in maternal delivery sera of women who had neonates with EOD caused by
that serotype were low, compared with levels in sera from women delivering infants who remained
healthy.1 However, different ‘protective’ levels have been defined in different studies as well as for the
different serotypes.
In a meta-analysis undertaken to compare the proportions of cases and controls with antibody levels
of ≥ 2 µg/ml, the odds of contracting iGBS were 6.6 [95% confidence interval (CI) 2.1 to 20.6] and 2.4
(95% CI 1.2 to 4.7) times greater in infants whose mothers had antibody levels of < 2 µg/ml for serotypes
III and Ia, respectively.20 A threshold of 1 µg/ml has also been proposed as a CoP for serotypes Ia and III.8
Thresholds are much higher in other studies using different case–control designs and different enzyme-linked
immunosorbent assay methods,21,22 which makes direct comparisons difficult.
Interpretation of studies is confounded by the different assay methods used and the lack of standardised
reference reagents for serotype-specific antibody levels. Therefore, further studies using standardised
methods are warranted.23
Defining a correlate of protection against invasive group B streptococcal disease
There is considerable evidence that serum immunoglobulin G (IgG) can protect infants against iGBS and
that this IgG is maternally derived as a result of natural maternal infection (i.e. colonisation). It is essential
to know precisely what level of serum IgG in women at delivery is protective so that this can be targeted
through vaccination. Protective levels can be estimated by comparing IgG from babies who are exposed
to GBS (through maternal colonisation) and go on to develop iGBS (cases), with IgG from babies who are
exposed to GBS (through maternal colonisation) but do not develop iGBS (controls). To do this, there
needs to be sufficient numbers of cases and controls to be able to define the protective level of IgG (the CoP)
with sufficient precision. Although the level of IgG in women at delivery is most often proposed as the CoP,
there is a predictable decline in IgG level from the mother to the fetus (transplacental transfer ratio) and,
subsequently, to the infant over the first 3 months of life (reflecting the half-life of maternal IgG). Measuring
IgG in the cord blood and at different time points in the infant can allow these concentrations to be compared
with maternal IgG to calculate the rate of antibody decline during the at-risk period of the first 3 months of
life. The level of IgG in the infant will be of particular relevance in cases of LOD where the median age at
disease onset is around 21 days.24
To generate a CoP, maternal delivery/cord sera from a cohort of mothers/babies must be collected
prospectively. When an infant subsequently develops iGBS the relevant delivery samples can be retrieved
for that infant and the antibody levels can be compared with those of suitable controls. The antibody levels
in the infant at the time of iGBS can also be obtained and may also be used to predict the levels present
at the time of delivery as it is not expected that these will change significantly between birth and the onset
of iGBS, at least for EOD.25
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Study rationale
From a UK perspective, we have recently seen an increasing burden of disease, despite a national (risk-based)
policy for IAP,10 and the UK National Screening Committee has recently recommended not to introduce a
national screening programme.26 The clinical effectiveness and cost-effectiveness of screening for GBS in
pregnancy is the objective of another Health Technology Assessment application (17/86, GBS3). Conversely,
the UK population has widely accepted the concept of maternal vaccination, with high coverage of maternal
pertussis vaccination (> 70%) and the first demonstration of its effectiveness, to our knowledge.27 The UK is
therefore in an excellent position to pursue the development, licensure and implementation of a maternal
vaccine against GBS.
Licensure and policy decisions for a candidate GBS vaccine would be significantly accelerated if an immune
marker was established as a CoP. Regulatory bodies, including the European Medicines Agency and the
Food and Drug Administration,28 have made it clear that they would now consider this approach to
licensure if robust evidence can be developed. Additionally, the UK Joint Committee on Vaccination and
Immunisation has indicated it would consider a recommendation for routine implementation of a vaccine
licensed on the basis of CoP – as it has for other recent vaccines (e.g. meningococcal C19).
The two critical gaps that have to be filled to make decisions on the use of such vaccines (both at the
regulatory and at the recommending body level) are (1) the development of a standardised immunoassay
to measure antibody levels that act as the correlates of natural immunity, supported by measurement
of functional antibody assays, and (2) a large biobank of sera to establish the correlate using these new
standardised assays. The first of these gaps is being addressed by a consortium of groups from academia,
public health and industry (led by co-applicant KLD, OPP1153630), and the second is the basis of this study.
Given the anticipated size and logistical complexities of the serocorrelates study that would be needed to
address this gap in knowledge, the aim of this initial feasibility study is to test key operational aspects of
the study design for the collection of a large bank of serum in the UK.
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To test the feasibility of collecting serum at delivery (maternal, cord or both) from a large cohort of
pregnant women.
Secondary objectives
To test the key operational aspects for a proposed large serocorrelates study:
l enrolment rate [the rate (proportion) of eligible women who are willing to participate in the delivery
blood collection study]
l maternal and/or cord blood collection rate
l key clinical exclusion data collection rate [weeks’ gestation at birth, receipt of IAP in labour (yes/no),
type of IAP (list), time between administration of IAP and delivery (in hours)]
l infant iGBS surveillance consent rate.
In a substudy of the main study above to assess:
l rectovaginal swab consent rate
l rectovaginal swab collection rate
l rectovaginal GBS colonisation rate
l rectovaginal GBS CPS serotype-specific colonisation rates.
In the substudy above, where samples of maternal/cord blood and rectovaginal swabs are all available,
to assess:
l infant blood sample consent rate
l infant Guthrie card consent rate
l infant Guthrie card collection rate.
To test the feasibility of collecting samples from iGBS cases:
l maternal blood and rectovaginal swab, and the baby blood consent and collection rate from the
participants of the iGBS study




l the impact of timing of processing and blood sample storage conditions on total IgG concentrations
l the serotype-specific GBS anti-CPS IgG concentrations in maternal serum and cord blood in subjects
colonised with GBS at delivery
l the correlation between two different culture techniques for detection of GBS in rectovaginal swabs –
enrichment culture medium and direct plating using selective agar.
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Chapter 3 Study design and methods
Study design
This was a prospective cohort study of pregnant women and their infants. The study design is shown in
Figures 1 and 2.
Participants
Inclusion criteria
l Those who were pregnant.
l Those who were aged ≥ 18 years.
l Those who were delivering at one of the selected hospitals.
l Those who consented to participate during the study period.
Exclusion criteria
As this was a feasibility study, there were no exclusion criteria other than inability to fulfil the inclusion
criteria above.
Ethics approval and research governance
Ethics approval for the study was given by the West Midlands – Solihull Research Ethics Committee (REC)
on 15 June 2018 with the reference number 18/WM/0147. The study was also approved by the Health
Research Authority (HRA) and Care Research Wales on 15 June 2018. Site-specific capacity and capability
was then given at the different research and governance departments of St George’s University Hospitals
NHS Foundation Trust, Kingston Hospital NHS Foundation Trust, Poole Hospital NHS Foundation Trust,
Surrey and Sussex Healthcare NHS Trust and Croydon Health Services NHS Trust.
Pregnant women attending five selected hospitals and due to deliver in the study period
Two hospitals Three hospitals
Maternal blood + cord blood +
rectovaginal swab


















to blood sample at 
1 or 2 or 3 months
of age
FIGURE 1 Flow chart for the feasibility study in five hospitals in London and the South East.
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The Antenatal and Newborn Research Advisory Committee approved the Guthrie card substudy on
3 October 2018.
During the study period, the protocol was amended three times, as follows.
Amendment 1 (5 July 2018)
1. Retrospective consent: permission was granted for retrospective written consent for sample collection
in those cases where there was insufficient time to obtain this before delivery and verbal consent was
previously recorded in the participant’s medical notes.
2. The GBS surveillance was extended to all the trusts of England and Wales to increase the number of
neonates and infants with iGBS recruited.
Amendment 2 (25 September 2018)
1. Permission was granted for the bacterial isolate from the national iGBS surveillance to be sent to the
St George’s microbiology laboratory to fully characterise the GBS strain.
Amendment 3 (9 October 2018)
1. Permission was granted to extend the study until 31 December 2018.
2. Permission was granted for consent to trace the Guthrie cards of those infants with iGBS included in





The study team will contact the site
clinical team
If parents give consent, samples will be
sent to St George’s laboratory: 2 ml of
infant blood, 5 ml of maternal blood,
rectovaginal swab and bacterial isolate
The study team tracks the infant’s
Guthrie card
Microbiologists
Notify case to PHE
24–72 hours
FIGURE 2 Flow chart for the national surveillance of iGBS. O&G, obstetrics and gynaecology; PHE, Public Health
England.
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Recruitment procedure
Patient recruitment at a site commenced after REC, HRA and local approvals and all subjects were screened
and consented by delegates of the chief investigator.
Study information was available on social media, posters on notice boards, institutional and GBSS websites
[https://gbss.org.uk/recent-research (accessed 30 January 2018)], letters, text messages or through direct
approach in antenatal clinics. Women had the opportunity to ask questions of the research team by
telephone or e-mail. If a woman was interested in participating, this was recorded on handheld notes
to ensure that delivery staff were aware of her interest.
Collection of delivery bloods
Following confirmation of consent, blood samples were obtained from the mother at any time during
labour (or within 48 hours of delivery) and/or from the cord once the placenta was delivered. At Kingston
and St George’s hospitals, both maternal blood and cord blood were collected. At other sites, maternal
blood was obtained if it was not possible to obtain a sample of cord blood after delivery.
Collection of swabs
At Kingston and St George’s hospitals only, pregnant women were asked to take part in the colonisation
study and a single vaginorectal swab was collected.
Collection of infant blood
At Kingston and St George’s hospitals, women who were participating in both the delivery blood
collection study and the colonisation study, and who were shown to be colonised with GBS, were also
invited to participate in the infant antibody kinetics substudy. A home visit or hospital appointment was
undertaken to collect an additional blood sample from the infant at 4, 8 or 12 weeks of age.
Collection of Guthrie cards
At Kingston and St George’s hospitals, women who were participating in both the delivery blood
collection study and the colonisation study were also invited to participate in the infant Guthrie card
collection substudy. Women were asked for consent to access their babies’ routine Guthrie card from the
National Screening Laboratory.
Invasive group B streptococcal disease surveillance
When a case of iGBS occurred at any participating hospital in England or Wales, the relevant paediatrician
was contacted by the study team and asked to recruit the mother and baby to the iGBS substudy. Women
were approached in the hospital and asked to provide a maternal and an infant blood sample.
Follow-up of babies
A follow-up telephone call was made to all consenting parents 90 days after their baby was born to
confirm whether or not their child had developed iGBS during this time period.
Informed consent
Informed consent from the participant, the legally authorised representative or the parents/guardians/
person with legal responsibility for children was obtained following explanation of the aims, methods,
benefits and potential hazards of the study.
Information about the study was given by one of the research midwives/clinical team and women had the
opportunity to ask questions. There was no minimum period between receiving information and providing
consent. Initially, formal written consent for participation in the study was taken at enrolment and then
confirmed with the mother verbally at, during or following delivery. In some cases, there was insufficient
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time to obtain written informed consent from participants who were presenting and being consented
in labour, although appropriately sensitised to the study. Following an amendment submitted to and
approved by the ethics committee (on 5 July 2018), we amended the protocol so that we were able to
obtain retrospective written consent after sample collection during delivery if verbal consent was previously
recorded in the participant’s notes. Written consent could be taken retrospectively within 24 hours of birth.
No data were collected until written informed consent was obtained and participants could withdraw at
any time.
Parents of infants identified as having a positive culture for GBS from a normally sterile site (blood or
cerebrospinal fluid) from participating hospitals in England and Wales were approached for consent to
obtain blood samples from the mother and baby during the acute admission and for collection of the GBS
isolate. Samples were collected when parents had had time to consider the information they had received
about the study and had given full written informed consent to the local study team.
A copy of the signed informed consent form along with a copy of the most recently approved patient
information sheet were given to the study participant. An original signed and dated consent form was
retained in the investigator site file and a third copy was placed in the medical notes.
Sample procedures
Delivery blood samples
Blood was obtained from the mother at any time during labour (or within 48 hours of delivery) and/or
from the cord once the placenta was delivered. A total of 5 ml of blood was collected into a BD® serum
separator tube (Becton, Dickinson and Company, Franklin Lakes, NJ, USA). Blood samples were transported
to the laboratories to be processed and the serum was collected into Eppendorf tubes (Thermo Fisher
Scientific, Waltham, MA, USA) and frozen at –20 °C to –80 °C for later processing.
Relevant clinical information was extracted from the mother’s handheld or hospital notes onto the case
report form. This included baby/babies gestation at birth (weeks), receipt of IAP (yes/no), type of IAP (list),
time between administration of first IAP and delivery (hours), recent blood transfusion (in last 3 months),
and elective caesarean section (yes/no).
Vaginal and rectal swabs
At Kingston and St George’s hospitals only, a single double-head rectovaginal swab was obtained at any
time from 35 weeks’ gestation up to (and including) delivery, either by the study midwife or by the mother
herself (with appropriate written guidance). The swab was inserted into the lower half of the vagina and
turned slowly clockwise once before removing and inserting past the anal sphincter into the low rectum.
The swabs were processed for GBS using validated methods (in an NHS laboratory) and reported using
standard NHS clinical pathways. In addition, we used a second, well-established, method for identification
of GBS recommended by the Centers for Disease Control and Prevention (but not currently in use in the UK):
one head of the swab was inserted into a transport media tube and transported to the local clinical
laboratory for processing in accordance with standard methods (direct plating onto selective agar), and the
other head was inserted into Lim broth (an enrichment culture media), sent to the research laboratory,
incubated for 6–24 hours and plated onto selective agar. The results (positive/negative) were communicated
to the site research midwives and the mother was informed by telephone (if GBS positive) and by letter
(if positive or negative). If GBS positive, women were subsequently managed in accordance with the Royal
College of Obstetrics and Gynaecology (RCOG) Greentop Guideline and were offered IAP if results were
available before delivery.29 Positive results were also serotyped with a latex agglutination test (LAT) or
polymerase chain reaction (PCR), if non-typeable by a LAT.
Collection of infant blood
At Kingston and St George’s hospitals only, women who were participating in both the delivery blood
collection study and the colonisation study and who were shown to be colonised with GBS were also
STUDY DESIGN AND METHODS
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invited to participate in the infant antibody kinetics substudy. In this substudy, babies born to colonised
mothers were randomised to have one blood sample obtained at 4, 8 or 12 weeks of age. Blood sampling
was undertaken by doctors using venepuncture or capillary sampling (2 ml) before blood was processed
and stored, as described above.
Collection of Guthrie cards
At Kingston and St George’s hospitals only, women who were participating in both the delivery blood
collection study and the colonisation study and had not received IAP were invited to participate in the
infant Guthrie card collection substudy. In this substudy, mothers were asked for permission to obtain a
single blood spot from the Guthrie card, which is obtained routinely in all babies at around 5 days of age.
This will be obtained from the National Screening Laboratory and stored for antibody analysis.
Antibody testing
Prior to the start of the study, serum samples were collected from 10 healthy non-pregnant volunteers
to assess the impact of timing of processing of blood samples and storage conditions on total IgG
concentrations. The effect on total IgG concentration was assessed at different times between sample
collection and sample processing (6 hours/10 hours/18 hours/24 hours/48 hours/72 hours/5 days/7 days).
Antibodies against the GBS-CPS were quantified using Luminex® multiplex assays (Luminex Corporation,
Austin, TX, USA) performed at St George’s, University of London, laboratories using the standardised assays
that have been established as part of a Gates Foundation-funded collaboration led by Kirsty Le Doare.
Infant follow-up
A follow-up telephone call was scheduled at 90 days after the baby’s birth to establish whether or not the
infant developed iGBS during this time period. This telephone call was made by the research midwives at
each site in order to keep personal data locally.
National invasive group B streptococcal disease surveillance
Microbiologists and paediatricians at all NHS trusts from England and Wales were informed about the
study through established research and clinical networks [British Paediatric Allergy, Immunity and Infection
Group (BPAIIG), Public Health England, the Neonatal Infection Network (neonIN) and the UK Paediatric
Vaccine Group]. Paediatricians and microbiologists were asked to make contact with study staff when a
case of iGBS occurred at their hospital. After having set up the site, the relevant paediatrician provided
study information to the parents and sought their permission for inclusion in the study. Following consent
from the parent, a sample of blood was obtained from the mother and from her baby and processed as
above. The participating mother was also asked to provide a single rectovaginal swab, taken either by
the midwife or by mother herself, to be processed as above. Furthermore, the study team contacted the
microbiology laboratory and asked for the bacterial isolate in order to culture and fully characterise the
GBS strain. These samples and the bacterial isolate were sent to and stored at St Georges, University of
London, in a linked anonymised fashion. In addition, parents were asked for their permission to collect the
Guthrie card of the infant.
Data collection
To standardise recruitment processes across the study sites and maximise data quality, we used Research
Electronic Data Capture (REDCap; 8.1.8, Vanderbilt University, Nashville, TN, USA)30 hosted at St George’s,
University of London. A range of data validation checks were carried out in both REDCap and Stata®
version 15 (StataCorp LP, College Station, TX, USA)27 to minimise erroneous or missing data.
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There is no formal sample size calculation as this is a pragmatic study conducted among a representative
network of hospitals that is intended to assess the feasibility of approaching a much larger network of
hospitals needed to achieve the main objective of this research. The proportions achieved against the
various study end points will allow sample size calculations to be made for the main study.
Statistical analysis
For the main end point of this feasibility study, we have undertaken a descriptive analysis. All analysis is
unadjusted. McNemar’s test was used to assess the exploratory objective concerning the two different GBS
culture methods.
Extensive efforts were undertaken to identify missing data. All missing data were excluded from the
final analyses.
STUDY DESIGN AND METHODS
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Chapter 4 Results
The analysis for this report is based on data collected from 2 July to 31 December 2018. The total numberof participants recruited was 1823, across the five sites (Table 1). We had partial recruitment with fewer
research midwives from 1 to 31 December. A summary of results is shown in Figure 3.
Objective 1
To test the feasibility of collecting serum at delivery (maternal, cord or both) from a large cohort of
pregnant women.
TABLE 1 Participants recruited by hospital
Hospital Start date End date Recruitment (n)
Croydon Health Services NHS Trust 20 August 2018 31 December 2018 166
Surrey and Sussex Healthcare NHS Trust 8 August 2018 30 November 2018 414
Kingston Hospital NHS Foundation Trust 10 July 2018 31 December 2018 257
Poole Hospital NHS Foundation Trust 11 July 2018 31 December 2018 621
St George’s University Hospitals NHS Foundation Trust 2 July 2018 31 December 2018 365
Total 2 July 2018 31 December 2018 1823
Pregnant women attending five selected hospitals and due to deliver
in study period
Two hospitals Three hospitals
Maternal blood + cord blood +





















FIGURE 3 Summary of results.
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Enrolment rate
Overall, 22% (95% CI 21% to 23%) of all women delivering during the study period consented to take
part in the feasibility study. However, when based on the number of women approached, the enrolment
rate was 74% (95% CI 71% to 76%) (Table 2). Two sites did not collect information on the number of
women approached, as the clinical teams approaching women did not accurately record when women
declined to participate.
Maternal and cord blood collection rates
In the two sites collecting both maternal and cord bloods, 60% and 53% of those recruited women had
samples collected, respectively (Table 3). In the three hospitals collecting cord blood only, the collection
rate was 85% (95% CI 83% to 87%) (Table 4).





study period, % (n/N)
Croydon Health Services NHS Trust 49 (166/340) 16 (166/1023)
Surrey and Sussex Healthcare NHS Trust – 30 (414/1370)
Kingston Hospital NHS Foundation Trust 64 (240/377) 10 (257/2462)
Poole Hospital NHS Foundation Trust 93 (621/667) 32 (621/1942)
St George’s University Hospitals NHS
Foundation Trust
– 15 (365/2458)
Total 74 (1027/1384)a (95% CI 71 to 76) 22 (1823/8340) (95% CI 21 to 23)
a Based on the three sites that were able to record all women who were approached during the study.






Kingston Hospital NHS Foundation Trust 81 (207/257) 79 (203/257)
St George’s University Hospitals NHS
Foundation Trust
45 (165/365) 34 (125/365)
Total 60 (372/622) 53 (328/622)






Maternal or cord blood/
total recruited, % (n/N)
Croydon Health Services
NHS Trust
73 (121/166) 0 (0/166) 73 (121/166)
Surrey and Sussex
Healthcare NHS Trust
94 (389/414) 6 (24/414) 99 (413/414)
Poole Hospital NHS
Foundation Trust
76 (469/621) 2 (14/621) 78 (483/621)
Total 82 (979/1201) 3 (38/1201) 85 (1017/1201) (95% CI 83 to 87)
a Maternal blood was collected only if cord blood not obtained.
RESULTS
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Key clinical data collection rate
Data on demographic and risk factors for iGBS were recorded in 90–100% of participants. Note that data
regarding ethnicity and infant sex were included from 1 November 2018. Data relating to antibiotic
administration were more difficult to collect retrospectively and represented a significant challenge to our
teams (Table 5).
Characteristics of participants recruited to the study are shown in Table 6.
If we compare data from recruited women (see Table 6) and women delivering at the five sites during the
last year (Table 7), we can assess the representativeness of our population. Overall, the sample from this
study is similar to the general population of pregnant women. With regard to ethnicity, Tables 6 and 7 show
that Croydon Health Services NHS Trust and St George’s University Hospitals NHS Foundation Trust have a
large non-white population. Regarding delivery type, more women with elective caesarean sections were
included in the study than are represented in the total study population.
The GBS-colonised women received benzylpenicillin in 62–85% of cases depending on the hospital site; the
first dose was given ≥ 4 hours before delivery in 50% of women with GBS-positive swabs (60/119). The
antibiotics given most frequently for reasons other than GBS colonisation were cefuroxime and cefalexin
(Table 8).
TABLE 5 Key clinical data collection rate
Key clinical data Collection rate, % (n/N)
Maternal demographic information
Maternal age 100 (1823/1823)
Ethnicity 48 (878/1823a)
Previous pregnancy 99 (1821/1823)
Previous GBS colonisation 99 (1054/1056b)
Previous baby with iGBS 99 (1050/1056b)
Birth information
Time between membrane rupture and delivery 92 (1676/1823)
Delivery type 93 (1690/1823)
Term delivery 93 (1690/1823)
Infant sex 59 (1082/1823a)
Positive swab before birth 91 (1666/1823)
Antibiotics if positive swab 90 (166/185c)
Antibiotic timing 54 (100/185c)
Antibiotics for other reasons 65 (1179/1823b)
a Collection of this item started after 1 November 2018.
b Number of women with previous pregnancies.
c Number of positive swabs.
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Maternal age group (years), n (%)
< 25 18 (10.8) 34 (8.2) 12 (4.7) 96 (15.5) 23 (6.3) 183 (10)
25–34 84 (50.6) 240 (58) 133 (51.8) 371 (59.7) 195 (53.4) 1023 (56.1)
35–41 57 (34.3) 125 (30.2) 107 (41.6) 145 (23.3) 132 (36.2) 566 (31)
> 41 7 (4.2) 15 (3.6) 5 (1.9) 9 (1.4) 15 (4.1) 51 (2.8)
Ethnicity, n (%) N = 120 N = 4 N = 31 N = 587 N = 136 N = 878
White British 36 (30a) 1 (25) 14 (45) 484 (82.5) 65 (47.8) 600 (68.3)
Black British 3 (2.5) 0 (0) 0 (0) 0 (0) 8 (5.9) 11 (1.3)
Asian British 7 (5.8) 2 (50) 4 (12.9) 2 (0.3) 6 (4.4) 21 (2.4)
Other white 23 (19.2) 0 (0) 11 (35.5) 42 (7.2) 23 (16.9) 99 (11.3)
Other black 20 (16.7) 0 (0) 0 (0) 3 (0.5) 2 (1.5) 25 (2.8)
Other Asian 24 (20) 0 (0) 1 (3) 12 (2) 6 (4.4) 43 (4.9)
Mixed 2 (1.7) 0 (0) 1 (3) 6 (1) 1 (0.7) 10 (1.1)
Others 5 (4.2) 1 (25) 0 (0) 38 (6.5) 25 (18.4) 69 (7.8)
Missing 46 (27.7) 410 (99) 226 (87.9) 34 (5.5) 229 (62.7) 945 (51.8)
Previous pregnancy, n (%)
Yes 114 (68.7) 253 (61.1) 124 (48.2) 387 (62.3) 178 (48.8) 1056 (57.9)
No 52 (31.3) 160 (38.6) 133 (51.8) 233 (37.5) 187 (51.2) 765 (42)
















Yes 4 (2.4) 23 (5.6) 17 (6.6) 11 (1.8) 13 (3.6) 68 (3.7)
No 87 (52.4) 156 (37.7) 99 (38.5) 367 (59.1) 60 (16.4) 769 (42.2)
Unknown 23 (13.9) 73 (17.6) 8 (3.1) 9 (1.4) 104 (28.5) 217 (11.9)
Missing 0 (0) 1 (0.2) 0 (0) 0 (0) 1 (0.3) 2 (0.1)
Previous baby













Yes 1 (0.6) 6 (1.4) 1 (0.4) 4 (0.6) 7 (1.9) 19 (1)
No 90 (54.2) 199 (48.1) 119 (46.3) 371 (59.7) 116 (31.8) 895 (49.1)
Unknown 23 (13.9) 47 (11.4) 4 (1.6) 12 (1.9) 50 (13.7) 136 (7.5)
Missing 0 (0) 1 (0.2) 0 (0) 0 (0) 5 (1.4) 6 (0.3)
Rupture of membranes, n (%)
< 18 hours 131 (78.9) 351 (84.8) 214 (83.3) 414 (66.7) 260 (71.2) 1370 (75.2)
≥ 18 hours 35 (21.1) 57 (13.8) 41 (16) 102 (16.4) 71 (19.5) 306 (16.8)
Missing 0 (0) 6 (1.4) 2 (0.8) 105 (16.9) 34 (9.3) 147 (8.1)
Delivery type, n (%)
Vaginal 86 (51.8) 261 (63) 132 (51.4) 280 (45.1) 214 (58.6) 973 (53.4)
Caesarean section with ROM 43 (25.9) 75 (18.1) 40 (15.6) 95 (15.3) 55 (15.1) 308 (16.9)
RESULTS
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37 (22.3) 74 (17.9) 83 (32.3) 141 (22.7) 74 (20.3) 409 (22.4)
Missing 0 (0) 4 (1) 2 (0.8) 105 (16.9) 22 (6) 133 (7.3)
Gestational age, n (%)
< 34 weeks 0 (0) 3 (0.7) 1 (0.4) 4 (0.6) 2 (0.5) 10 (0.5)
≥ 34 weeks 166 (100) 408 (98.6) 254 (98.8) 512 (82.4) 340 (93.2) 1680 (92.2)
Missing 0 (0) 3 (0.7) 2 (0.8) 105 (16.9) 23 (6.3) 133 (7.3)
Infant’s sex, n (%) 144 79 120 509 230 1082
Male 71 (49.3a) 40 (50.6) 61 (50.8) 248 (48.7) 115 (50) 535 (49.4)
Female 73 (50.7) 39 (49.4) 59 (49.2) 261 (51.3) 115 (50) 547 (50.6)
Missing 22 (13.3) 335 (80.9) 137 (53.3) 112 (18) 135 (37) 741 (40.6)
Positive swab before birth, n (%)
Yes 28 (16.9) 31 (7.5) 28 (10.9) 30 (4.8) 68 (18.6) 185 (10.1)
No 138 (83.1) 380 (91.8) 227 (88.3) 465 (74.9) 271 (74.2) 1481 (81.2)
Missing 0 (0) 3 (0.7) 2 (0.8) 126 (20.3) 26 (7.1) 157 (8.6)
ROM, rupture of membrane.
a Percentage applies to total number where data known.
Note that data regarding ethnicity and infant sex were included from 1 November 2018. This explains the missing data in
these two areas.























Maternal age (years) (mean) 31 31.8 32 30.5 32.6 31.6
Ethnicity (%)
White 36 80 63 0 46 56
Asian 14 11 10 0 16 13
Black 17 3 3 0 10 8
Mixed 9 3 1 0 2 4
Other ethnic groups 24 2 7 0 10 11
Not stated 0 1 16 0 16 8
Missing 0 0 0 100 0 20
Delivery type (%)
Caesarean section 26 30 29 32 25 28
Vaginal 51 70 71 68 75 68
Missing 23 0 0 0 0 4
continued
DOI: 10.3310/hta23670 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 67
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Carreras-Abad et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of
Southampton Science Park, Southampton SO16 7NS, UK.
17
























< 37 weeks 4 9 6 0 9 7
≥ 37 weeks 64 91 94 0 91 85
Missing 32 0 0 100 0 26
Infant’s sex (%)
Male 51 51 0 51 51 51
Female 49 49 0 49 49 49
Missing 0 0 100 0 0 20
Note
Missing values for Poole Hospital NHS Foundation Trust regarding ethnicity and gestational age, as well as missing values
for Kingston Hospital NHS Foundation Trust, regarding infant’s sex were excluded to calculate total percentages.























swab (N) 28 31 28 30 68 185
Yes, n (%) 21 (75) 27 (87.1) 22 (78.6) 20 (66.7) 29 (42.6) 119 (64.3)
No, n (%) 7 (25) 4 (12.9) 6 (21.4) 10 (33.3) 20 (29.4) 47 (25.4)
Missing, n (%) 0 (0) 0 (0) 0 (0) 0 (0) 19 (27.9) 19 (10.3)
Antibiotics type (N) 23 29 22 20 26 120
Benzylpenicillin, n (%) 13 (61.9) 23 (85.2) 18 (81.8) 17 (85) 21 (72.4) 92 (77.3)
Clindamycin, n (%) 3 (14.3) 2 (7.4) 2 (9.1) 1 (5) 1 (3.4) 9 (7.6)
Others, n (%) 7 (25) 4 (12.9) 2 (7) 2 (6.6) 4 (5.9) 19 (4.2)
Antibiotics timing if
positive swab (N) 21 27 22 20 29 119
< 2 hours before birth, n (%) 2 (9.5) 7 (25.9) 6 (27.3) 4 (20) 3 (10.3) 22 (18.5)
2–4 hours before birth, n (%) 3 (14.3) 3 (11.1) 4 (18.2) 7 (35) 1 (3.4) 18 (15.1)
> 4 hours before birth, n (%) 16 (76.2) 16 (59.3) 12 (54.5) 8 (40) 8 (27.6) 60 (50.4)
Missing, n (%) 0 (0) 1 (3.7) 0 (0) 1 (5) 17 (58.6) 19 (16)
Antibiotics for other
reasons (N) 166 414 257 621 365 1823
Yes 44 (26.5) 36 (8.7) 48 (18.7) 232 (37.4) 21 (5.8) 381 (20.9)
No 92 (55.4) 219 (52.9) 118 (45.9) 272 (43.8) 97 (26.6) 798 (43.8)
Missing 30 (18.1) 159 (38.4) 91 (35.4) 117 (18.8) 247 (67.7) 644 (35.3)
RESULTS
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Infant invasive group B streptococcal disease surveillance
The consent rate for the 90-day follow-up telephone call to be made was 100% (1823/1823).
The telephone calls started 90 days after the first baby was born and, because of the short study period,
applied only to those recruited in the first month of the study. No cases of iGBS were detected in the
telephone follow-up that had not already been reported by the hospital team (Table 9).






















Antibiotics type for other
reasons (N) 43 33 48 230 14 368
Benzylpenicillin, n (%) 1 (0.3) 7 (1.8) 0 (0) 3 (0.8) 3 (0.8) 14 (3.7)
Clindamycin, n (%) 3 (0.8) 1 (0.3) 0 (0) 1 (0.3) 0 (0) 5 (1.3)
Cefalexin, n (%) 18 (4.7) 3 (0.8) 0 (0) 7 (1.8) 7 (1.8) 35 (9.2)
Ceftriaxone, n (%) 0 (0) 1 (0.3) 0 (0) 2 (0.5) 0 (0) 3 (0.8)
Cefuroxime, n (%) 20 (5.2) 21 (5.5) 47 (12.3) 217 (57) 2 (0.5) 307 (80.6)
Co-amoxiclav, n (%) 0 (0) 0 (0) 1 (0.3) 0 (0) 2 (0.5) 3 (0.8)
Vancomycin, n (%) 1 (0.3) 0 (0) 0 (0) 0 (0) 0 (0) 1 (0.3)
Note
Total numbers for ‘antibiotics type’ can be higher than the number of women who received antibiotics because some
women received more than one antibiotic.


























Telephone call attempt 1, n (%)
Yes 40 (24.1) 51 (12.3) 20 (7.8) 80 (12.9) 100 (27.4) 291 (16)
No 126 (75.9) 363 (87.7) 237 (92.2) 541 (87.1) 265 (72.6) 1532 (84)
Telephone call 1:
successful, n (%) (N = 40) (N = 51) (N = 20) (N = 80) (N = 100) (N = 291)
Yes 23 (57.5) 14 (27.5) 6 (30) 35 (43.8) 40 (40) 118 (40.5)
No 17 (42.5) 37 (72.5) 14 (70) 45 (56.3) 60 (60) 173 (59.5)
Telephone call attempt 2,
n (%) (N = 17) (N = 37) (N = 14) (N = 45) (N = 60) (N = 173)
Yes 17 (100) 32 (86.5) 5 (35.7) 36 (80) 32 (53.3) 122 (70.5)
No 0 (0) 5 (13.5) 9 (64.3) 9 (20) 28 (46.7) 51 (29.5)
Telephone call 2:
successful, n (%) (N = 17) (N = 32) (N = 5) (N = 36) (N = 32) (N = 122)
Yes 3 (17.6) 4 (12.5) 0 (0) 16 (44.4) 11 (34.4) 34 (27.9)
No 14 (82.4) 28 (87.5) 5 (100) 20 (55.6) 21 (65.6) 88 (72.1)
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Rectovaginal swab consent and collection rate
Of the 622 women enrolled at the two hospitals taking part in the colonisation study, rectovaginal consent
was 100% and the rectovaginal collection rate was 99% (Table 10). The overall GBS colonisation rate was
22% (Table 11).
Rectovaginal group B streptococcus serotype-specific colonisation rates
A total of 115 out of 120 positive swabs were serotyped with a rapid LAT and PCR was performed when
the sample was found to be non-typeable by LAT. The most common serotype was serotype III (30%),
followed by Ia (25%), II (16%), Ib (16%), V (14%) and IV (1%) (Figure 4).
TABLE 10 Rectovaginal swab consent and collection rate
Hospital




Kingston Hospital NHS Foundation Trust 100 (257/257) 99 (255/257)
St George’s University Hospitals NHS
Foundation Trust
100 (365/365) 98 (359/365)
Total 100 (622/622) 99 (614/622)










20 (49/247) 3 (8/255) 22 (57/255)
St George’s University Hospitals
NHS Foundation Trust
20 (71/350) 3 (9/359) 22 (80/359)
Total 20 (120/597) 3 (17/614) 22 (137/614)
(95% CI 19% to 26%)
a Women who were already known to have a positive swab during this pregnancy were also invited to participate but the












FIGURE 4 The GBS serotype distribution in colonised women.
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Risk factors for group B streptococcus colonisation
No statistically significant differences were found between colonised and non-colonised women regarding
demographic and risk factors for iGBS except having had a positive GBS swab in a previous pregnancy,
which was more common in colonised women (Table 12).
TABLE 12 Demographic and risk factors by colonisation status
Demographic Colonised, n (%) Non-colonised, n (%) Total, n (%) p-value
137 (22.3) 477 (77.7) 614 (100)
Hospital 0.984
Kingston Hospital NHS Foundation Trust 57 (22.4) 198 (77.6) 255 (41.5)
St George’s University Hospitals NHS
Foundation Trust
80 (22.3) 279 (77.7) 359 (58.5)
Maternal age group (years) 0.159
< 25 6 (17.1) 29 (82.9) 35 (5.7)
25–34 66 (20.5) 256 (79.5) 322 (52.4)
35–41 57 (24.1) 180 (75.9) 237 (38.6)
> 41 8 (40) 12 (60) 20 (3.3)
Ethnicity 0.124
White British 35 (44.9) 43 (55.1) 78 (12.7)
Black British 5 (62.5) 3 (37.5) 8 (1.3)
Asian British 3 (30) 7 (70) 10 (1.6)
Other white 22 (64.7) 12 (35.3) 34 (5.5)
Other black 1 (50) 1 (50) 2 (0.3)
Other Asian 5 (71.4) 2 (28.6) 7 (1.1)
Mixed 0 (0) 2 (100) 2 (0.3)
Others 16 (66.7) 8 (33.3) 24 (3.9)
Missing 50 (11.1) 399 (88.9) 449 (73.1)
Previous pregnancy 0.803
Yes 68 (22.7) 231 (77.3) 299 (48.7)
No 69 (21.9) 246 (78.1) 315 (51.3)
GBS colonisation in previous pregnancy 68 (22.7) 231 (77.3) 299 (100) 0.041
Yes 12 (41.4) 17 (58.6) 29 (9.7)
No 34 (21.5) 124 (78.5) 158 (52.8)
Unknown 22 (19.8) 89 (80.2) 111 (37.1)
Missing 0 (0) 1 (100) 1 (0.3)
Previous baby with iGBS 68 (22.7) 231 (77.3) 299 (100) 0.427
Yes 3 (42.9) 4 (57.1) 7 (2.3)
No 54 (23.1) 180 (76.9) 234 (78.3)
Unknown 11 (20.8) 42 (79.2) 53 (17.7)
Missing 0 (0) 5 (100) 5 (1.7)
continued
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Infant blood sample collection rates
In the two hospitals participating in both the colonisation and the blood collection studies, consent to
obtain an infant blood sample if the mother was GBS positive and consent to obtain Guthrie card samples
were both 100% (Table 13). However, we were able to contact the families of 61% of eligible infants and
to collect blood samples from 59% of infants whose family we contacted (Table 14). Samples were taken
from seven infants at 1 month, 14 infants at 2 months and 13 infants at 3 months of life.
TABLE 12 Demographic and risk factors by colonisation status (continued )
Demographic Colonised, n (%) Non-colonised, n (%) Total, n (%) p-value
Rupture of membranes 0.96
< 18 hours 106 (22.5) 365 (77.5) 471 (76.7)
≥ 18 hours 25 (22.7) 85 (77.3) 110 (17.9)
Missing 6 (18.2) 27 (81.8) 33 (5.4)
Delivery type 0.825
Vaginal 74 (21.6) 268 (78.4) 342 (55.7)
Caesarean section with ROM 23 (24.5) 71 (75.5) 94 (15.3)
Caesarean section without ROM 36 (23.1) 120 (76.9) 156 (25.4)
Missing 4 (18.2) 18 (81.8) 22 (3.6)
Gestation 0.349
< 34 weeks 0 (0) 3 (100) 3 (0.5)
≥ 34 weeks 133 (22.6) 455 (77.4) 588 (95)
Missing 4 (17.4) 19 (82.6) 23 (3.7)
Infant’s sex 0.541
Male 42 (25.1) 125 (74.9) 167 (27.2)
Female 38 (22.8) 129 (77.2) 167 (27.2)
Missing 57 (20.4) 223 (79.6) 280 (45.6)
Analysis based on an unpaired t-test. p-values of < 0.05 were considered significant.
TABLE 13 Infant blood sample consent rates
Infant sample Consent rate, % (n/N)
Blood sample 100 (622/622)
Guthrie card 100 (622/622)




Infant blood sample collected/infants
contacted, % (n/N)
Kingston Hospital NHS Foundation Trust 56 (27/48) 48 (13/27)
St George’s University Hospitals NHS
Foundation Trust
66 (31/47) 68 (21/31)
Total 61 (58/95) 59 (34/58)
RESULTS
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Objective 2
To test the feasibility of collecting samples from iGBS cases.
Participants from the feasibility study
There were five notifications of iGBS within the participants of the main study, all from Poole Hospital.
The clinical presentation was EOD in all cases, and three cases occurred in conjunction with cases of
maternal sepsis. Samples of maternal blood, a rectovaginal swab, infant blood and the bacterial isolate
were collected from four mother–infant pairs (Table 15). The fifth case was unable to be recruited as the
infant was admitted to a different hospital.
Participants from national invasive group B streptococcal disease surveillance
The protocol was amended on 6 September 2018 to include national (England and Wales) surveillance
for iGBS. This resulted in 18 notifications, from which 11 cases were recruited into the study (58%).
Seven cases were not recruited as there was insufficient time to set up the site before the patient was
discharged. All parents approached consented to participation in the study. The clinical presentation was
EOD in nine and LOD in two cases (both of which were preterm infants) (Table 16).














1 Male 15 hours 40.5 > 18 hours Cefuroxime +
metronidazole
< 2 hours Sepsis II
2 Female Birth 39 < 18 hours Cefuroxime +
metronidazole
> 4 hours Sepsis V
3 Male Birth 33.3 > 18 hours Erythromycin > 4 hours Sepsis Ib
4 Female Birth 40.4 < 18 hours Cefuroxime +
metronidazole
< 2 hours Sepsis II
ROM, rupture of membranes.














1 Male 18 hours 40+2 < 18 hours No – Sepsis III
2 Male 14 hours 42 < 18 hours Cefuroxime +
metronidazole
< 2 hours Sepsis II
3 Female 2 hours 41 < 18 hours No – Sepsis Ia
4 Female 16 hours 38+3 > 18 hours No – Sepsis Ia
5 Female < 24 hours 37+4 < 18 hours No – Sepsis+
meningitis
Unknown
6 Female 6 hours 39 > 18 hours No – Sepsis Ia
7 Female 7 hours 40 > 18 hours No – Sepsis III
8 Male 42 days 30+2 > 18 hours No – Sepsis III
9 Female 3 days Term < 18 hours No – Sepsis IV
10 Male 5 hours 40 > 18 hours No – Sepsis III
11 Male 53 days 25 < 18 hours No – Sepsis II
ROM, rupture of membranes.
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In total, serotyping data were available for 14 of the 15 iGBS cases (including the four cases from the
feasibility study); the distribution is shown in Figure 5. None of the infants whose samples were collected
died during the study.
Exploratory objectives
Impact of timing of processing and blood sample storage conditions on
immunoglobulin G concentrations
There was an acceptable impact on total IgG concentrations for periods of time from 6 hours up to 1 week
between sample collection and spinning time (Figure 6). The average time of spinning and freezing samples
varied between hospitals but was generally within 1 week of sample receipt (Table 17). St. George’s Hospital






















































FIGURE 6 Total IgG concentrations by time between sample collection and centrifuging of sample. Guthrie refers
to IgG detection from Guthrie cards.
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Serotype-specific group B streptococcus anticapsular polysaccharide immunoglobulin G
concentrations in maternal serum, cord and infant blood in subjects colonised with
group B streptococcus at delivery
We were able to identify serotype-specific GBS anti-CPS IgG concentrations in maternal serum and cord
blood. Antibody concentrations generally declined between birth and 3 months of age.
The correlation between two different culture techniques for detection of group B
streptococcus in rectovaginal swabs: enrichment culture medium versus direct plating
using selective agar
The enrichment culture medium was more sensitive than direct plating at identifying GBS from rectovaginal
swabs (Table 18). A total of 97% (116/120) of positive swabs were identified by enriched culture medium
(ECM) plus plating onto selective agar as compared with 75% (90/120) by direct plating onto selective agar
(p < 0.001, McNemar’s test).



















23 1.4 1.0 0.0 4.0 23
MB spin to freeze 23 0.0 0.2 0.0 1.0
CB collection to
spin
388 1.8 1.2 0.0 7.0 389






349 6.5 6.5 0.0 44.0 366
MB spin to freeze 366 6.4 6.6 0.0 42.0
CB collection to
spin
480 7.0 6.7 0.0 44.0 524





13 4.2 8.1 0.0 31.0 13
MB spin to freeze 13 0.0 0.0 0.0 0.0
CB collection to
spin
457 1.5 1.8 0.0 33.0 458
CB spin to freeze 458 0.0 0.4 0.0 8.0
CB, cord blood; MB, maternal blood.




selective agar negative Number of swabs
ECM positive 86 30 116
ECM negative 4 477 481
Total (n) 90 507 597
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Feedback from sites
We undertook site visits to all of the participating hospitals on two occasions during the study period.
Feedback from the local teams resulted in changes to study design, including recruitment strategies and
data and sample collection. Details of feedback from sites can be found in Appendix 1.
RESULTS
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Chapter 5 Discussion
The ultimate aim of this work was to determine the serocorrelates of protection against the majorGBS serotypes causing disease in young infants in order to facilitate GBS vaccine licensure. Given the
anticipated size and logistical complexities of the study that would be needed to address this, the aim of
this initial feasibility study was to test key operational aspects of the proposed study design.
The feasibility study recruited 1823 women from five hospitals over a period of time, ranging from 3.5 to
6 months. This represented 22% of all women delivering during this period, but 74% of those women
who were approached (95% CI 71% to 76%). Once consent was obtained, there was a very high rate of
blood sample collection [i.e. 85% (95% CI 83% to 87%) for the three hospitals that were collecting cord
samples only]. This is very reassuring because it is cord blood collection from a large number of women
nationally (180,000) that is required in the main study. The significance of this group for the large study is
that it will form the cohort from which cases are captured (i.e. to determine the antibody levels in the cord
blood of babies who go on to develop iGBS at < 3 months of age).
There was notable variation in recruitment across the sites, with one site (Poole Hospital NHS Foundation
Trust) achieving a very high (93%) recruitment rate of those approached (32% overall). A number of factors
might account for this and our observations at sites and, in particular, the feedback from sites revealed
different recruitment strategies and examples of best practice. For example, by following such feedback,
we sought and gained ethics approval to allow retrospective consent for cord blood collection, which led to
improved recruitment and collection of samples. Engagement of the whole clinical midwife team in the study
by enthusiastic research staff was found to be more effective than recruitment by the research staff alone;
sending out information sheets to parents prior to approaching them was also shown to result in better
recruitment at one site. Such observations (see Appendix 1) can now be implemented in a future study.
Other work undertaken during the study has also allowed us to define practical issues around sample
collection that can now be applied in a future study. For example, the lack of impact on IgG concentrations
for periods of time between blood sample collection and spinning time, ranging from 6 hours to 1 week
(substudy), will enable sites to batch samples before spinning to maximise efficiency savings. These results
differ from previous guidelines that recommended a maximum of 6 hours between collection and spinning.31
The demographics of the recruited women suggest important differences in the populations served by
the different hospitals, which is a major consideration when selecting these hospitals for the feasibility
study. Croydon Health Services NHS Trust, for example, had a very high proportion of black and Asian
mothers (45%) compared with Poole Hospital NHS Foundation Trust (3%). Such factors may also have
influenced the success of recruitment in the different sites: Poole Hospital NHS Foundation Trust recruited
93% of those approached (32% overall) whereas Croydon Health Services NHS Trust recruited 49% of
those approached (16% overall). This can be explored further by comparing the characteristics of those
recruited, by site, with the characteristics of all women at the site, but does also suggest the need for
additional strategies (e.g. translation of the patient information sheet into relevant local languages).
In the two hospitals undertaking the substudy (rectovaginal swab, maternal blood and cord blood), the
enrolment rate was (understandably) lower: 10–15% of all women delivering during the period of the study.
Again, rates of blood sample collection varied by hospital: 34–45% at St George’s University Hospitals NHS
Foundation Trust versus 79–81% at Kingston Hospital NHS Foundation Trust. A key difference here was the
timing of approach and sample collection, with lower rates associated with recruitment in antenatal clinics
and higher rates with recruitment in the labour ward, which suggested the latter as the better model for a
future study. By contrast, collection rates of vaginorectal swabs were extremely high at both sites, indicating
that pregnant women are keen to participate in swabbing studies and are (probably) highly motivated to
understand more regarding GBS disease. The significance of this substudy is that it defines the control group
needed to address the serocorrelates of protection (i.e. the antibody levels in women who are known to be
colonised at delivery and did not receive IAP but whose infants do not develop iGBS in < 3 months).
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For those women who consented, collection of the key clinical information needed to interpret antibody
concentrations (in controls) was also generally high, although some information, such as ethnicity and
infant sex, was collected only in the final 2 months of the study.
Colonisation rates (22%, 95% CI 19% to 26%) and the serotype distribution among colonising isolates
are consistent with those found in previous studies.3 However, as these studies were conducted a number
of years ago, this study provides contemporary data that are essential for planning new studies (e.g. GBS3)
and for modelling new interventions (e.g. vaccination).
Parents uniformly agreed to being followed up by a telephone call once their baby was 3 months of age,
indicating this to be a satisfactory method to follow up babies for later disease (and to ensure that suitable
controls are chosen). However, actually telephoning these parents was very labour intensive, which
suggested that alternatives, such as data linkage to national databases and networks, may be a more
effective method of identifying infants who have not developed iGBS.
During the study period, parental consent and all relevant samples were collected from 15 infants with
invasive GBS disease: four cases from the study cohort (of 1823; incidence 2.2/1000 live births) and 11
from national surveillance, which was instituted part-way through the study period. This provides strong
reassurance that our system can successfully obtain relevant samples from cases of disease; this is critical
in addressing the objectives of the serocorrelates of protection study. It will be imperative that sites are
set up in advance of the main study to ensure that samples can be collected while the infant is still in
the hospital.
An important substudy was to identify the best laboratory methods for detecting GBS colonisation. Of the
100 microbiology laboratories in the UK, only approximately 20% are currently equipped to undertake
ECM analysis of GBS swabs. The majority of UK microbiology laboratories use direct plating onto selective
agar in a semiautomated system. We compared direct plating versus incubation in ECM before plating
onto selective agar. The latter method identified 97% of the positive GBS swabs compared with 75% using
the standard method. These considerations are important as the UK moves towards fewer, more centralised
laboratories that require automation to manage the throughput of samples within clinical microbiology.
Our results have important implications for sample size calculations in future UK studies, such as the GBS3 trial.
Parents were very keen, in principle, to have blood obtained from their infants over the first 3 months of
life. We enrolled 34 infants, born to colonised women, into the antibody kinetics substudy and preliminary
data indicate a waning of antibodies between birth and 3 months of life. This will help us understand the
relationship between the antibody at the time of iGBS with the antibody in the cord blood of that baby and
of the mother. A serocorrelate of protection in the baby will be important in determining protection, but
protective antibody at the time of acute disease might overestimate (or underestimate) the true protective
level. Our results will therefore enable this interpretation in the main study.
Limitations and recommendations
In summary, this initial feasibility study has been able to assess key operational aspects of the large study
that is needed to define the serocorrelates of protection against iGBS.
The main limitation is that we were not able to recruit the (hypothetical) target of 4000 women, mainly
because of the short period of the study and insufficient staff dedicated to it. However, we believe that
we have recruited a suitable number to allow us to draw conclusions that will now aid the design and
co-ordination of the main trial. This includes the clinical data to be collected, how they are recorded,
when to approach women in pregnancy and how the issue of cord blood collection can be managed.
For example, we believe that an opt-out approach, whereby cord blood sampling would become part of
normal routine practice, would help to recruit the large cohort we are aiming for in the serocorrelates
study. We propose to assess this in a continuation of this study.
DISCUSSION
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Chapter 6 Next steps
As described and justified earlier, we propose that to define the serocorrelates of protection against themost common serotypes of GBS causing infant disease in the UK will require a case–control study of
suitable size.
Sample size calculation
Based on previous correlates of risk reduction studies,8,20,22 correlates that give risk reductions of 80–90%
are feasible and acceptable. An 80% reduction in a case–control study implies an odds ratio of 0.2.
The precision around 0.2 for varying case sample sizes and varying proportion of controls with IgG levels
above the potential correlate levels (‘cuts’) is shown in Appendix 2.
Cases
Based on the incidence of iGBS from our 2014 national surveillance study (0.9/1000 live births up to
90 days of age),10 we anticipate being able to collect at least 150 iGBS case samples (EOD and LOD) over
2 years of collection from 180,000 women.
Controls
The number of controls is based on the need for a 3 : 1 ratio of controls to cases (see Appendix 2).
Of 150 iGBS cases, we would expect approximately 100 cases of serotype III disease and, thus, 300 suitable
controls are required to be matched to them (i.e. women colonised with serotype III, who do not receive
IAP and whose babies do not develop iGBS). As indicated previously, and confirmed by the results of
the feasibility study, with a control group of 5000 women we would expect to recruit approximately
380 healthy term infants born to GBS serotype III-colonised women who have not received IAP.
Possible strategies for completing the case–control study
On discussion with the GBS3 trial team, it is apparent that the most efficient way of recruiting the control
group would be by extending the feasibility study rather than by recruiting these women within the GBS3
trial. This is because, in the context of the GBS3 trial, the women who would potentially be eligible to
form the control group (i.e. women who are having a swab performed) will (essentially) all go on to receive
IAP if they are found to be GBS colonised. By definition, if a woman has received IAP then she would be
ineligible to be in the control group as the receipt of IAP will alter the risk of EOD in her baby. It is likely
that women in the ‘standard of care’ arm in GBS3 will be less likely to receive IAP but, as they are not having
a swab performed, they would not be eligible as controls. Based on the data from this feasibility study, in which
8.3% of women at the three sites that did not participate in the colonisation substudy happened to have
a positive swab obtained before birth (89/1072, excluding missing data), we would need to recruit 12,000
women to identify the 1000 in the ‘standard of care’ arm who have been opportunistically swabbed and
are colonised in order to capture the 380 infants born to mothers colonised with GBS serotype III.
An alternative for generating the control group would be to identify women in GBS3 who have a positive
GBS swab result, but (for whatever reason) do not receive IAP. This is not our preferred method, as it
seems likely that they will be an unusual (and potentially unrepresentative) group of women. However,
more importantly, the GBS3 team have indicated that it will not be possible to identify (at an individual
level vs. a unit level) those women who actually receive IAP. Owing to the design of the GBS3 study, it will
therefore be impossible to identify these women.
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The feasibility study has allowed us to identify best practice in recruiting women to have a rectovaginal
swab, cord blood and key clinical information collected. We believe that the control group of 5000 women
could therefore be recruited using the five sites that have participated in the feasibility study; all sites have
expressed a willingness to do so, subject to sufficient funding to support recruitment.
We have recruited around 600 women with swabs in 4 months from two sites (75 per site per month).
We therefore estimate that we will require an additional 12 months at five sites to complete control
group recruitment (i.e. 75 women per month per site = 75 × 5 = 375 women per month; 375 women ×
12 months = 4500 women), plus 3 months for site set-up (renewal of ethics and local approvals) and to
ensure staff coverage within the midwifery teams (total 15 months extension). This would ensure that we
achieve our target of 5000 women, of whom we expect 380 to be colonised with GBS serotype III and
who would serve as our control group for iGBS III cases, recruited in the main study.
Invasive group B streptococcal disease cases from the proposed main
trial (GBS3)
As indicated, cord blood will be required from a cohort of approximately 180,000 women. The feasibility
study has indicated that recruitment to a study in which cord blood is to be obtained can be very high when
a study midwife has the opportunity to approach a woman to obtain consent (74%, 95% CI 71% to 76%).
However, as it was possible to approach only a minority of women during the study period because of the
individual consent approach, the overall recruitment rate (22% of all births during the study period, 95% CI
21% to 23%) was much lower. Performing clinical trials for an intrapartum intervention has historically been
challenging because of issues related to consent in an ‘emergency’ setting. Advances in experience and
knowledge of delivering high-quality and high-impact research in labour have however recently emerged.
A consent pathway developed by the GBS3 trial group32 now features in the RCOG guidance on intrapartum
consent.33 Recent examples of successful intrapartum emergency studies include deferred or immediate
cord clamping in preterm birth,34 glyceryl trinitrate for retained placenta,35 tranexamic acid for treatment
of post-partum haemorrhage,36 with further trials under way [e.g. the High Or Low Dose Syntocinon for
delay in labour (HOLDS) trial ISRCTN 99841044 (Kenyon S, Taylor R, Hewston R, Johnston T, Hinshaw K,
Middleton L, et al. Birmingham Women's NHS Foundation Trust, March 2016 to June 2019) and ANODE
ISRCTN: 1116698437]. Feedback from the participating sites suggests that obtaining cord blood from women
in labour using an opt-out strategy would be both realistic and acceptable. We propose testing this strategy
more formally through patient groups and by seeking ethics committee advice.
To identify those infants in this cohort in GBS3 who develop iGBS we propose to undertake surveillance via
Public Health England and specific paediatric clinical networks (BPAIIG and neonIN). We have successfully
identified cases through these networks in the feasibility study and have been able to capture 15 cases
of iGBS in a short period of time. This provides confidence in our approach. An additional advantage to
extending the feasibility study as proposed above would be to continue to test the feasibility of national
surveillance and to embed it as a routine, in preparation for the GBS3 study.
In addition, an extension would allow us to test the hypothesis that antibody concentration at the time of
acute disease equates to antibody concentration from cord blood. We have already enrolled 27 babies born
to healthy women into our antibody kinetics study (eight colonised with serotype III). However, to ensure
that we understand the relationship between antibody in the acute disease phase and in a healthy infant
exposed to GBS, we now need to undertake the kinetics study in cases of GBS disease up to 3 months
of life. Collecting acute serum from 50 infants with serotype III disease will enable us to interpret antibody
in health and disease up to 90 days of life. If infant antibody at the time of acute disease proves to be
an accurate reflection of cord blood antibody for that infant, this would make a major difference to the
design of the GBS3 trial as it would negate the need for the full 180,000 cord sera samples. This would
mean that we would need blood from only 150 cases of iGBS serotype III disease rather than collecting
cord blood from 180,000 women. We can resolve this during the extended feasibility study.
NEXT STEPS
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Data-sharing statement
All data requests should be submitted to the corresponding author for consideration. Access to
anonymised data may be granted following review and agreement of the Steering Committee.
Patient data
This work uses data provided by patients and collected by the NHS as part of their care and support. Using
patient data is vital to improve health and care for everyone. There is huge potential to make better use
of information from people’s patient records, to understand more about disease, develop new treatments,
monitor safety, and plan NHS services. Patient data should be kept safe and secure, to protect everyone’s
privacy, and it’s important that there are safeguards to make sure that it is stored and used responsibly.
Everyone should be able to find out about how patient data are used. #datasaveslives You can find out
more about the background to this citation here: https://understandingpatientdata.org.uk/data-citation.
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Appendix 1 Feedback from sites, looking towards
the ‘big study’
BOX 1 Feedback from sites, looking towards the ‘big study’
Recruiting methods
Feedback
l Retrospective consent has improved recruitment and collection of cord blood.
l Having time to explain the study before consenting increases the enrolment rate.
l Sending the information sheet prior to delivery reduces midwife face-to-face time.
l Main refusal reasons: language barriers, taking part in research, using samples for future research,
rectovaginal swabs and taking samples from babies.
Tips
l An opt-out approach, where swabs and blood collection would be part of normal routine, would be well
accepted and easier for recruitment.
l Information of the study prior to delivery would be useful: letters, social media.
l A patient information sheet translated to other languages would be helpful, especially Urdu.
Data collection
Feedback
l REDCap, as a tool for case report form, has been well accepted and appreciated. It does not take long to
fill it.
l Data may be missing, especially data collected during labour, if research midwives are not present.
Tips
l Collaboration of clinical midwives is essential.
Sample collection
Feedback
l It has been easier to recruit in labour wards in order to collect blood samples.
l Maternal blood is easy to collect from women who need a cannula (caesarean sections, inductions).
l Vaginorectal self-swab collection (with midwife support) helps to increase the consent rate.
Tips
l It is essential to have a team involved on labour wards (cord blood team, midwives, obstetricians, nurses).
l Having staff dedicated exclusively to cord blood collection would be helpful.
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Invasive group B streptococcal disease surveillance
Feedback
l Telephone calls might be time-consuming and not so effective to detect LOD.
Tips
l A national surveillance could be more effective to recruit iGBS cases following the logistics represented in
the flow chart (Figure 7).










The study team will
contact the clinical
team 24–48 hours
Send the consumables and
required documentation
24–48 hoursIf parents give consent,
samples will be sent back in
the package provided
FIGURE 7 The iGBS national surveillance. O&G, obstetrics and gynaecology.
BOX 1 Feedback from sites, looking towards the ‘big study’ (continued)
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Appendix 2 Precision of correlates of risk
reduction for serotype-specific group B streptococcus
disease estimates according to different sample sizes
Based on previous GBS CoP studies,2–4 GBS serocorrelates that give risk reductions of 80–90% are feasible.A reduction of 80% in a case–control study implies an odds ratio of 0.2. The precision around 0.2 for
varying case sample sizes and varying proportion of controls with IgG levels above the potential CoP levels
(‘cuts’) is shown above with three controls per case. Thus, if 50% of controls have levels above the cut-off
point, with 30 cases the 95% CI around an 80% reduction is 43% to 93%; with 90 cases it is 63% to 89%
(bold values in table below).




N= 30 cases and
N= 90 controls
N= 90 cases and
N= 270 controls
N= 150 cases and
N= 450 controls
70% 0.08 to 0.49 0.12 to 0.33 0.13 to 0.30
50% 0.07 to 0.57 0.11 to 0.37 0.13 to 0.32
30% 0.05 to 0.81 0.09 to 0.45 0.11 to 0.37
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